File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Cluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis

TitleCluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis
Authors
Keywordsbiomarker
CD44
kidney inflammation
lupus nephritis
tubulo-interstitial fibrosis
Issue Date1-Oct-2024
PublisherFrontiers Media
Citation
Frontiers in Immunology, 2024, v. 15 How to Cite?
AbstractIntroduction: CD44 is a transmembrane glycoprotein implicated in tissue inflammation and fibrosis. We investigated its role in kidney inflammation and fibrosis in a murine model of lupus nephritis (LN), and the clinico-pathological association of serum CD44 level in patients with biopsy-proven Class III/IV ± V LN. Methods: NZB/W F1 mice were treated with control IgG or anti-CD44 monoclonal antibody for 4 weeks and disease parameters assessed. Serum CD44 level in LN patients was determined by ELISA. Control groups included healthy subjects and patients with non-renal SLE or non-lupus renal disease. Results: CD44 expression was absent in the normal kidney, but it was expressed in proximal and distal tubular epithelial cells and infiltrating cells in renal biopsies from patients with active proliferative LN. ScRNA-Seq datasets confirmed that CD44 was predominantly expressed in tubular cells and all immune cells identified in LN patients including tissue resident, inflammatory and phagocytic macrophages, Treg cells, effector and central memory CD4+ T cells, resident memory CD8+ T cells and naïve and activated B cells. Treatment of NZB/W F1 mice with anti-CD44 antibody preserved kidney histology and reduced proteinuria, tubulo-interstitial infiltration of CD3+, CD4+ and CD19+ immune cells, and mediators of kidney fibrosis compared to Control mice. Longitudinal studies showed that serum CD44 level increased prior to clinical renal flare by 4.5 months and the level decreased after treatment. ROC curve analysis showed that CD44 level distinguished patients with active LN from healthy subjects and patients with quiescent LN, active non-renal lupus, and non-lupus CKD (ROC AUC of 0.99, 0.96, 0.99 and 0.99 respectively). CD44 level correlated with leukocyte infiltration and interstitial inflammation scores in active LN kidney biopsies. Discussion: Our findings suggest that CD44 plays a pathogenic role in renal parenchymal inflammation and fibrosis in active LN and monitoring CD44 may facilitate early diagnosis of flare.
Persistent Identifierhttp://hdl.handle.net/10722/357433
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWong, Caleb C.Y.-
dc.contributor.authorGao, Lucy Y.-
dc.contributor.authorXu, Yuesong-
dc.contributor.authorChau, Mel K.M.-
dc.contributor.authorZhang, Danting-
dc.contributor.authorYap, Desmond Y.H.-
dc.contributor.authorYing, Shirley K.Y.-
dc.contributor.authorLee, Cheuk Kwong-
dc.contributor.authorYung, Susan-
dc.contributor.authorChan, Tak Mao-
dc.date.accessioned2025-06-24T00:30:08Z-
dc.date.available2025-06-24T00:30:08Z-
dc.date.issued2024-10-01-
dc.identifier.citationFrontiers in Immunology, 2024, v. 15-
dc.identifier.urihttp://hdl.handle.net/10722/357433-
dc.description.abstractIntroduction: CD44 is a transmembrane glycoprotein implicated in tissue inflammation and fibrosis. We investigated its role in kidney inflammation and fibrosis in a murine model of lupus nephritis (LN), and the clinico-pathological association of serum CD44 level in patients with biopsy-proven Class III/IV ± V LN. Methods: NZB/W F1 mice were treated with control IgG or anti-CD44 monoclonal antibody for 4 weeks and disease parameters assessed. Serum CD44 level in LN patients was determined by ELISA. Control groups included healthy subjects and patients with non-renal SLE or non-lupus renal disease. Results: CD44 expression was absent in the normal kidney, but it was expressed in proximal and distal tubular epithelial cells and infiltrating cells in renal biopsies from patients with active proliferative LN. ScRNA-Seq datasets confirmed that CD44 was predominantly expressed in tubular cells and all immune cells identified in LN patients including tissue resident, inflammatory and phagocytic macrophages, Treg cells, effector and central memory CD4+ T cells, resident memory CD8+ T cells and naïve and activated B cells. Treatment of NZB/W F1 mice with anti-CD44 antibody preserved kidney histology and reduced proteinuria, tubulo-interstitial infiltration of CD3+, CD4+ and CD19+ immune cells, and mediators of kidney fibrosis compared to Control mice. Longitudinal studies showed that serum CD44 level increased prior to clinical renal flare by 4.5 months and the level decreased after treatment. ROC curve analysis showed that CD44 level distinguished patients with active LN from healthy subjects and patients with quiescent LN, active non-renal lupus, and non-lupus CKD (ROC AUC of 0.99, 0.96, 0.99 and 0.99 respectively). CD44 level correlated with leukocyte infiltration and interstitial inflammation scores in active LN kidney biopsies. Discussion: Our findings suggest that CD44 plays a pathogenic role in renal parenchymal inflammation and fibrosis in active LN and monitoring CD44 may facilitate early diagnosis of flare.-
dc.languageeng-
dc.publisherFrontiers Media-
dc.relation.ispartofFrontiers in Immunology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectbiomarker-
dc.subjectCD44-
dc.subjectkidney inflammation-
dc.subjectlupus nephritis-
dc.subjecttubulo-interstitial fibrosis-
dc.titleCluster of differentiation-44 as a novel biomarker of lupus nephritis and its role in kidney inflammation and fibrosis-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fimmu.2024.1443153-
dc.identifier.pmid39411720-
dc.identifier.scopuseid_2-s2.0-85206517587-
dc.identifier.volume15-
dc.identifier.eissn1664-3224-
dc.identifier.isiWOS:001330971900001-
dc.identifier.issnl1664-3224-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats